Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Oncoinvent
Entity

Oncoinvent

Tracked across 2 events · 13 articles · First seen Jun 18, 2026 · Last active Aug 11, 2026

Sentiment
70
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 70
Tech
Oncoinvent Radspherin Phase 2 Milestone
Impact: Oncoinvent announced reaching the 50% patient recruitment milestone in its Phase 2 trial for Radspherin, indicating progress in its clinical development and potential for future commercial success.
Jun 18, 2026 · 7 articles
2 70
Tech
Oncoinvent publishes Radspherin dosimetry results
Oncoinvent, a biotech company developing Radspherin, an alpha radiopharmaceutical for treating peritoneal metastases, announced the publication of clinical dosimetry data in the The Journal of Nuclear Medicine. The publication, titled 'Normal Tissue Dosimetry of Intraperitoneal…
Impact: Oncoinvent is the developer of Radspherin and the primary subject of the announcement. The publication of favorable dosimetry data supports its clinical program and could enhance its commercial prospects.
Aug 11, 2026 · 6 articles
Key Actions (1)
70 Oncoinvent reached milestoneOncoinvent publishes...
ERGEN INTELLIGENCE
Track Oncoinvent live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.